Sitting Down With… Sarah Coupland, Chair of Pathology, University of Liverpool, Consultant Histopathologist at Liverpool Clinical Labs, Registrar for the Royal College of Pathologists, and President of PathSoc
Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy.